Navigation Links
United Therapeutics Corporation Reports Second Quarter 2013 Financial Results
Date:7/25/2013

SILVER SPRING, Md., July 25, 2013 /PRNewswire/ --  

  • Total Revenues of $280.6 million
  • Earnings per Share of $1.60 per Basic Share or $1.52 per Diluted Share
  • Earnings Before Non-Cash Charges of $3.29 per Basic Share, or $3.11 per Diluted Share
  • United Therapeutics Corporation (NASDAQ: UTHR) today announced its financial results for the second quarter ended June 30, 2013.

    "I am very pleased with our second quarter results and the continued strong growth of our core business," said Martine Rothblatt, Ph.D., United Therapeutics' Chairman and Chief Executive Officer. "We continue to assist more patients than ever to manage pulmonary arterial hypertension while we also continue to develop new possibilities for the future, such as the implantable Remodulin pump."

    Total revenues for the quarter ended June 30, 2013 were $280.6 million, up from $225.6 million for the quarter ended June 30, 2012. Net income for the quarter ended June 30, 2013 was $79.9 million or $1.60 per basic share, compared to $72.3 million or $1.37 per basic share for the same quarter in 2012. Gross margin from sales was $245.2 million for the quarter ended June 30, 2013, compared to $192.2 million for the same quarter last year. Earnings before non-cash charges(1) for the quarter ended June 30, 2013 were $163.7 million, compared to $127.7 million for the same quarter in 2012.(1)

    See definition of earnings before non-cash charges, a non-GAAP financial measure, and a reconciliation of net income to earnings before non-cash charges below.Financial Results for the Three Months Ended June 30, 2013 Revenues

    The table below summarizes the components of net revenues (dollars in thousands):Three Months Ended June 30,Percentage Change20132012Cardiopulmonary products:Remodulin

    $

    '/>"/>
    SOURCE United Therapeutics Corporation
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. United Therapeutics Corporation to Announce Second Quarter 2013 Financial Results Before Market Open on Thursday, July 25, 2013
    2. Before the Bell Scans: Pharmacyclics, United Therapeutics, Impax Laboratories, and Star Scientific
    3. Mapi Pharma Granted United States Patent for Pain Relief Medication "Tapentadol"
    4. Centre for Sight First in the United Kingdom to Utilize TrueVision® 3D Visualization During Femtosecond Laser Cataract Surgery
    5. Prevagen® is the Number One Branded Memory Supplement in the United States
    6. SPIE on Global Team Proposing ‘international Year of Light’ at United Nations
    7. United Airlines and AltAir Fuels to Bring Commercial-Scale, Cost-Competitive Biofuels to Aviation Industry
    8. Despite Lucentiss Recent Expanded Label for Diabetic Macular Edema, Avastin Remains the Preferred Intravitreal Therapy for Diabetic Macular Edema in the United States
    9. Atlantic Peptides Teams Up with a United Kingdom Company to Offer cGMP Peptides and API
    10. SoundConnect Announces Lync Release in the United States
    11. United Therapeutics Corporation To Announce First Quarter 2013 Financial Results Before Market Open On Thursday, April 25, 2013
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:11/18/2014)... RPS Diagnostics (RPS®) – a developer ... its third annual partnership of the Centers for ... Antibiotics Week from November 17-23. , Get Smart ... to highlight the coordinated efforts of CDC, state ... partners to provide education about the importance of ...
    (Date:11/18/2014)... (PRWEB) November 18, 2014 Alanda ... and Transparency Reporting solutions, announced today that a ... using its Consummate Provider™ solution in both the ... a Global, SaaS based, Data Quality remediation portal, ... their third party Providers improve their ability to ...
    (Date:11/18/2014)... 2014 Array Architects is proud of ... to the nation's hospitals and health systems. It is ... dedicating their careers to the advancement of both the ... her respective field, Laura Silvoy has been chosen to ... Winter Simulation Conference. , Laura will present her ...
    (Date:11/18/2014)... DOYLESTOWN, Pa. , Nov. 18, 2014  Novira ... therapies for curative treatment of chronic hepatitis B virus ... , M.D., was appointed to its Scientific Advisory Board ... Brian join our SAB," said Christian S. Schade ... wealth of clinical development experience which will be invaluable ...
    Breaking Biology Technology:RPS Again Partners with the CDC in Support of the 2014 Get Smart About Antibiotics Week 2RPS Again Partners with the CDC in Support of the 2014 Get Smart About Antibiotics Week 3Alanda Software Completes Successful Implementation of Global Data Quality & Vendor Management Solution for Top Tier Global Biopharmaceutical Company 2Array Healthcare Simulation Expert Slated to Speak at Winter Simulation Conference 2Novira Therapeutics Announces Appointment of Brian F. Daniels, M.D., to its Scientific Advisory Board 2Novira Therapeutics Announces Appointment of Brian F. Daniels, M.D., to its Scientific Advisory Board 3
    ... Feb. 10 Microdosing or Phase 0 clinical ... an imperative phase of the drug development process ... niche capability providers in preclinical testing and technology ... partnerships and alliances, fuelling growth opportunities in this ...
    ... an MBA-student organized event, will be held February 19-20 in Philadelphia. ... from Healthcare Services, Investment, Pharma, Biotech, and Medical Device sectors. ... ... 2009 Wharton Health Care Business Conference , an MBA-student organized ...
    ... DSM Biologics and Crucell N.V. (Euronext, Nasdaq: ... they have entered into an agreement with Bioceros B.V. ... Under the terms of the agreement, Bioceros will be ... the PER.C6(R) cell line located in the European Union.Karen ...
    Cached Biology Technology:Frost & Sullivan Sees Microdosing as Compelling Advantage for Big Pharma 2Frost & Sullivan Sees Microdosing as Compelling Advantage for Big Pharma 314th Annual Wharton Health Care Business Conference to Feature CEOs from WebMD, McKesson, Humana and Given Imaging 2DSM and Crucell Sign Agreement with Bioceros to Serve as Pre-Approved Cell Line Generation Partner of PER.C6(R) Cell Line Proteins 2DSM and Crucell Sign Agreement with Bioceros to Serve as Pre-Approved Cell Line Generation Partner of PER.C6(R) Cell Line Proteins 3DSM and Crucell Sign Agreement with Bioceros to Serve as Pre-Approved Cell Line Generation Partner of PER.C6(R) Cell Line Proteins 4DSM and Crucell Sign Agreement with Bioceros to Serve as Pre-Approved Cell Line Generation Partner of PER.C6(R) Cell Line Proteins 5
    (Date:11/6/2014)... cancer deaths occur because of metastasis, yet progress ... been slow. , "It,s been particularly challenging to ... Gujral, research fellow in systems biology at Harvard ... detected until after they,ve already metastasized." , Gujral ... that should help researchers better understand how metastasis ...
    (Date:11/5/2014)... career to understanding the Earth,s climate and communicating ... deputy director and regional climatologist for the Western ... Redmond has more than three decades of experience ... data to the general public. , At its ... December 15-19, 2014 the American Geophysical Union (AGU) ...
    (Date:11/4/2014)... Temple University School of Medicine announced today that ... initiative funded by the Bill & Melinda Gates ... Obstetrics, Gynecology and Reproductive Sciences; and Vice Chair ... School of Medicine will pursue an innovative global ... Biomarkers to Assess Fetal Neurodevelopment.", Grand Challenges Explorations ...
    Breaking Biology News(10 mins):Migration negation 2Migration negation 3Nevada climatologist to be honored at AGU Fall Meeting for lifetime of public outreach 2Temple University School of Medicine receives Grand Challenges Explorations grant 2
    ... DAVIS--Mosquito traps that reek like latrines may be no ... team led by chemical ecologist Walter Leal has discovered ... making humans hold their noses. The synthetic mixture, ... just as enticing to Culex mosquitoes as the current ...
    ... and South Africa have created a biophysical methodology ... potentially remedy even substantial hearing loss. The authors ... the ear to recognize frequencies originally associated with ... the open-access journal PLoS Computational Biology . ...
    ... Presenting new research about national, home and business security ... of Houston professor and his colleagues has become the ... to surveillance. Two professors and two ... Institute of Electrical and Electronics Engineers International Conference on ...
    Cached Biology News:No more big stink: scent lures mosquitoes, but humans can't smell it 2Biophysical method may help to recover hearing 2National security remedies among topics at surveillance confab 2National security remedies among topics at surveillance confab 3
    Request Info...
    ... 5B15-5B-11E. Immunogen: Synthetic peptide derived from ... protein. Specificity: Specific for the ... Western blots it identifies the target band ... (positive controls: deglycosylated secreted media from primary ...
    Lipid-rich bovine serum albumin for cell culture. It is chromatographically purified and has an IgG content 1.0% (w/w)....
    Prepared with distilled water. Yeast extract solution is autolyzed at 150 g/L....
    Biology Products: